U.S. Partnership Revolutionizes Reversal of Ticagrelor Effects with Bentracimab!

SERB Pharmaceuticals and SFJ Pharmaceuticals proudly announce a groundbreaking development in the pharmaceutical realm: SERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ. This marks a major milestone in the global specialty pharmaceutical and drug development industries, as SERB and SFJ continue to push the boundaries of what’s possible.

Bentracimab is a revolutionary monoclonal antibody fragment designed to counter the antiplatelet effects of ticagrelor. Approved by AstraZeneca as Brilinta®, ticagrelor is a P2Y12 platelet inhibitor used to treat heart attack, stroke, acute coronary syndromes, and coronary artery disease.

With the potential approval of Bentracimab, doctors can now provide their patients with the antithrombotic benefits of ticagrelor while having the ability to control bleeding in emergency situations, such as surgery or a major bleed. This could drastically reduce the risk of vascular events and death.

SFJ and SERB are joining forces to submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) later this year, in order to bring bentracimab to market. SFJ is responsible for the ongoing clinical trials, ensuring that this promising new drug will benefit patients everywhere.

Jeremie Urbain, Executive Chairman of SERB Pharmaceuticals, enthusiastically announced the acquisition of bentracimab as an exciting step in the company’s strategy to grow and invest in innovative, biologic products for critical care conditions.

SERB is thrilled to partner with SFJ, the renowned leaders in late-stage drug development, to make this life-saving medicine available to healthcare professionals and the patients they care for.

SFJ is thrilled to join forces with Jeremie and the SERB team to help fast-track bentracimab to those in need. With its potential benefits, SFJ and SERB are confident that they can swiftly secure the approval of the US FDA for bentracimab.

According to CEO Robert DeBenedetto, “We are excited to be part of this important journey and believe that our collaboration with SERB will accelerate the process of bringing bentracimab to patients.”

Bentracimab, recently granted Breakthrough Therapy Designation by the FDA, has demonstrated impressive results in the ongoing Phase 3 trial REVERSE-IT. A prespecified interim analysis published in the New England Journal of Medicine Evidence showed that this innovative drug can immediately and sustainably reverse the antiplatelet effects of ticagrelor with high affinity and specificity, and has been well tolerated with only minor adverse events reported. Bentracimab is paving the way for a new era of safer and more effective treatments.

SFJ and SERB have recently come to an agreement, though the specifics of their financial terms remain undisclosed. Leopoldo Zambeletti served as SFJ’s advisor while Evercore acted as advisor to SERB in the deal.

SERB Pharmaceuticals is a global leader in specialty pharmaceuticals, providing vital medicines to those suffering from life-threatening and rare diseases for over 30 years. As a fully integrated company, we have a deep understanding of the complexities of emergency care, and the experience and capabilities to acquire, develop and manufacture our medicines to the highest standards.

Our expansive antidote portfolio is the broadest in the world, and covers medical countermeasures for potential chemical, biological, radiological and nuclear risks. Through our secure supply chain, we make our medicines available to patients and their families worldwide, offering them hope and a chance at recovery. In the US, we operate as BTG Pharmaceuticals.

About SFJ Pharmaceuticals®

SFJ is a revolutionary drug development company that offers a unique, custom-tailored clinical development partnering model to the world’s leading pharmaceutical and biotechnology firms. With at-risk funding and global clinical development oversight, SFJ ensures successful regulatory submissions for some of the most promising drug development programs.

Our mission is to provide financial backing and pharmaceutical development expertise to accelerate the development of life-saving and life-enhancing drugs, so that patients can access them sooner.

Leave a Comment